SystImmune
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SystImmune sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
SystImmune: 6 sponsored US clinical trials, 5 recruiting.
SystImmune sponsors 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastroesophageal-junction Cancer, with 2 trials.
Upper-quartile sponsor footprint
SystImmune sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Therapeutic Areas
What is open in the SystImmune pipeline
5 recruiting of 6 indexed (83% open).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Gastroesophageal-junction Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SystImmune: open-pipeline peers nationwide
Peers matched on 6 registered trials and 83% open enrollment, not the therapeutic-area sidebar.
SystImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 83% open enrollment (± trial volume)
- Centessa Pharmaceuticals (UK) Limited · 83% recruiting · 6 trials
- Meyer Children's Hospital IRCCS · 83% recruiting · 6 trials
- Tyra Biosciences · 83% recruiting · 6 trials
- Johnson & Johnson Enterprise Innovation · 86% recruiting · 7 trials
Related
What to do with this SystImmune page
6 registered trials is a research-attention snapshot, not an endorsement of SystImmune or any single study.
- 5 of SystImmune's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Gastroesophageal-junction Cancer is the condition SystImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastroesophageal-junction Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SystImmune pipeline card: 6 registered trials from official public datasets.Report a data error.